Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010

H. Quon; D. A. Loblaw

doi:10.3747/co.v17i0.709

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Article

1 September 2010

Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010

and

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada

Author to whom correspondence should be addressed.

Curr. Oncol.2010, 17(s2), 38-44;https://doi.org/10.3747/co.v17i0.709

Version Notes

Order Reprints

Abstract

The discovery of androgen deprivation therapy (ADT) has been one of the most important advances in the treatment of prostate cancer. Here, the indications for the use of ADT are reviewed, together with the data supporting each indication. The settings for ADT use include cytoreduction; combined ADT and radiotherapy; pathologic node-positive disease; and recurrent, metastatic, or progressive prostate cancer.

Keywords:

androgen antagonists; hormonal anti-neoplastic agents; combined-modality therapy; disease progression; orchiectomy; prostatic neoplasms; radiotherapy; prostatectomy

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Multimodal Approaches to High-Risk Prostate Cancer

Prevention Strategies in Prostate Cancer